Date: 2017-08-09
Type of information: Private placement
Company: Spark Therapeutics (USA - PA)
Investors:
Amount: $380.4 million
Funding type: private placement
Planned used:
Others:
- • On August 9, 2017, Spark Therapeutics announced the closing of the previously announced underwritten public offering of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission, including the exercise in full by the underwriters of their option to purchase an additional 690,789 shares from Spark at the public offering price of $76.00 per share, less the underwriting discount. The exercise of the option brought the total number of shares sold in the offering to 5,296,053, and increased the aggregate net proceeds to Spark to approximately $380.4 million, after deducting underwriting discounts and before offering expenses.
- • On August 3, 2017, Spark Therapeutics announced the pricing of an underwritten public offering of 4,605,264 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission at a public offering price of $76.00 per share, before offering discounts.
- The offering will result in aggregate net proceeds of approximately $330.8 million to Spark, after deducting underwriting discounts and before offering expenses. In addition, Spark has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 690,789 shares at the public offering price, less the underwriting discount. The offering is expected to close on or about August 9, 2017, subject to customary closing conditions.
- • On August 2, 2017, Spark Therapeutics announced that it has commenced an underwritten public offering of $300,000,000 in shares of its common stock.
- Spark also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
- J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC will act as bookrunning managers for the offering.
- The shares are being offered by Spark pursuant to an automatically effective shelf registration statement (including a prospectus) that has been filed with the U.S. Securities and Exchange Commission.
Therapeutic area:
Is general: Yes
